Immune checkpoint inhibitors for advanced non-small cell lung cancer: emerging sequencing for new treatment targets
- PMID: 29209522
- PMCID: PMC5703392
- DOI: 10.1136/esmoopen-2017-000200
Immune checkpoint inhibitors for advanced non-small cell lung cancer: emerging sequencing for new treatment targets
Abstract
Lung cancer is the leading cause of cancer-related deaths in the world. Immune checkpoint inhibitors (ICI) stimulate cytotoxic lymphocyte activity against tumour cells. These agents are available for the treatment of non-small cell lung cancer (NSCLC) after failure of platinum-based therapy. One recent study has demonstrated that ICI monotherapy was superior to platinum-based chemotherapy for first-line treatment. Nevertheless, this benefit was only for a minority of the population (30%) whose tumour programmed death receptor ligand-1 (PD-L1) expression was above 50%. Therefore, several strategies are under investigation. One option for patients with PD-L1 expression lower than 50% may be the combination of ICI with platinum-based chemotherapy or with ICIs against different targets. However, all of these combinations are at an early stage of investigation and may be very expensive or toxic, producing several harmful adverse events.
Keywords: atezolizumab; immunotherapy; nivolumab; non-small cell lung cancer; pembrolizumab.
Conflict of interest statement
Competing interests: None declared.
Figures
References
-
- Altekruse SF, Kosary CL, Krapcho M, et al. . SEER Cancer statistics review, 1975-2007. Bethesda, MD, 2010.
-
- Feinstein AR, Wells CK. A clinical-severity staging system for patients with lung cancer. Medicine 1990;69:1–33 http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med3&NEWS=N&AN=... 10.1097/00005792-199001000-00001 - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials